Core Viewpoint - BioNTech SE will announce its financial results for Q3 2025 on November 3, 2025, and will host a conference call and webcast for discussion [1] Group 1: Financial Results Announcement - The financial results for the third quarter of 2025 will be disclosed on November 3, 2025 [1] - A conference call and webcast will take place at 8:00 a.m. EST (2:00 p.m. CET) on the same day for investors and analysts [1] Group 2: Accessing the Conference Call - Participants can register for the live conference call via a provided link, with dial-in numbers and a PIN sent post-registration [2] - It is recommended to register at least one day in advance [2] - The slide presentation and audio of the webcast will be accessible through a specified link [2] Group 3: Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4] - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [4] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, and targeted therapies like antibody-drug conjugates and CAR T cell therapies [4] - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [4] - BioNTech has established collaborations with various global pharmaceutical companies, including Pfizer and Bristol Myers Squibb [4]

Core Insights - BioNTech SE, in collaboration with InstaDeep Ltd., will host its second AI Day on October 1, 2025, in London, focusing on BioNTech's AI strategy and its applications in the company's pipeline and internal processes [1] Company Overview - BioNTech is a global biopharmaceutical company specializing in next-generation immunotherapy, developing innovative therapies for cancer and serious diseases [3] - The company utilizes a variety of computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals [3] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and CAR T cell therapies [3] - The company is also researching multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [3] - BioNTech has established partnerships with several global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Roche Group [3]